The global Central Nervous System (CNS) Drug market size was valued at USD 119620 million in 2023 and is forecast to a readjusted size of USD 188330 million by 2030 with a CAGR of 6.7% during review period.
Central nervous system (CNS) disease is a broad category of conditions in which the brain does not function as it should, limiting health and the ability to function. The condition may be an inherited metabolic disorder; the result of damage from an infection, a degenerative condition, stroke, a brain tumor or other problem; or arise from unknown or multiple factors. Movement disorders such as Parkinson鈥檚 disease, dystonia, and essential tremor are central nervous system conditions. What they have in common is the loss of sufficient, intact nervous system circuits that orchestrate functions as varied as memory formation (in Alzheimer鈥檚) or voluntary motion (in movement disorders).
The presence of strong pipeline products is expected to drive the central nervous system therapeutics market over the forecast period. Major pharmaceutical companies are focusing on new treatments to prevent or improve symptoms of neurological diseases.
Report includes an overview of the development of the Central Nervous System (CNS) Drug industry chain, the market status of MS Therapeutics (Prescription Drugs, OTC), Antipsychotic Drugs (Prescription Drugs, OTC), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Central Nervous System (CNS) Drug.
Regionally, the report analyzes the Central Nervous System (CNS) Drug markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Central Nervous System (CNS) Drug market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Central Nervous System (CNS) Drug market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Central Nervous System (CNS) Drug industry.
The report involves analyzing the market at a macro level:
麻豆原创 Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., Prescription Drugs, OTC).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Central Nervous System (CNS) Drug market.
Regional Analysis: The report involves examining the Central Nervous System (CNS) Drug market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
麻豆原创 Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Central Nervous System (CNS) Drug market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Central Nervous System (CNS) Drug:
Company Analysis: Report covers individual Central Nervous System (CNS) Drug players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Central Nervous System (CNS) Drug This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (MS Therapeutics, Antipsychotic Drugs).
Technology Analysis: Report covers specific technologies relevant to Central Nervous System (CNS) Drug. It assesses the current state, advancements, and potential future developments in Central Nervous System (CNS) Drug areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Central Nervous System (CNS) Drug market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
麻豆原创 Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
麻豆原创 Segmentation
Central Nervous System (CNS) Drug market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
麻豆原创 segment by Type
Prescription Drugs
OTC
麻豆原创 segment by Application
MS Therapeutics
Antipsychotic Drugs
Depression Drugs
Epilepsy Drugs
Others
麻豆原创 segment by players, this report covers
Johnson & Johnson
Pfizer Inc
Novartis AG
GSK
Eli Lilly
Teva
Otsuka Pharmaceutical Co., Ltd
Biogen Inc
Boehringer Ingelheim
Roche
UCB
Tekeda
Shanghai Fosun
Jiangsu Nhwa Pharmaceutical Co., Ltd.
麻豆原创 segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Argentina and Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Central Nervous System (CNS) Drug product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Central Nervous System (CNS) Drug, with revenue, gross margin and global market share of Central Nervous System (CNS) Drug from 2019 to 2024.
Chapter 3, the Central Nervous System (CNS) Drug competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2019 to 2030.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Central Nervous System (CNS) Drug market forecast, by regions, type and application, with consumption value, from 2025 to 2030.
Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Central Nervous System (CNS) Drug.
Chapter 13, to describe Central Nervous System (CNS) Drug research findings and conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.
1 麻豆原创 Overview
1.1 Product Overview and Scope of Central Nervous System (CNS) Drug
1.2 麻豆原创 Estimation Caveats and Base Year
1.3 Classification of Central Nervous System (CNS) Drug by Type
1.3.1 Overview: Global Central Nervous System (CNS) Drug 麻豆原创 Size by Type: 2019 Versus 2023 Versus 2030
1.3.2 Global Central Nervous System (CNS) Drug Consumption Value 麻豆原创 Share by Type in 2023
1.3.3 Prescription Drugs
1.3.4 OTC
1.4 Global Central Nervous System (CNS) Drug 麻豆原创 by Application
1.4.1 Overview: Global Central Nervous System (CNS) Drug 麻豆原创 Size by Application: 2019 Versus 2023 Versus 2030
1.4.2 MS Therapeutics
1.4.3 Antipsychotic Drugs
1.4.4 Depression Drugs
1.4.5 Epilepsy Drugs
1.4.6 Others
1.5 Global Central Nervous System (CNS) Drug 麻豆原创 Size & Forecast
1.6 Global Central Nervous System (CNS) Drug 麻豆原创 Size and Forecast by Region
1.6.1 Global Central Nervous System (CNS) Drug 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
1.6.2 Global Central Nervous System (CNS) Drug 麻豆原创 Size by Region, (2019-2030)
1.6.3 North America Central Nervous System (CNS) Drug 麻豆原创 Size and Prospect (2019-2030)
1.6.4 Europe Central Nervous System (CNS) Drug 麻豆原创 Size and Prospect (2019-2030)
1.6.5 Asia-Pacific Central Nervous System (CNS) Drug 麻豆原创 Size and Prospect (2019-2030)
1.6.6 South America Central Nervous System (CNS) Drug 麻豆原创 Size and Prospect (2019-2030)
1.6.7 Middle East and Africa Central Nervous System (CNS) Drug 麻豆原创 Size and Prospect (2019-2030)
2 Company Profiles
2.1 Johnson & Johnson
2.1.1 Johnson & Johnson Details
2.1.2 Johnson & Johnson Major Business
2.1.3 Johnson & Johnson Central Nervous System (CNS) Drug Product and Solutions
2.1.4 Johnson & Johnson Central Nervous System (CNS) Drug Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.1.5 Johnson & Johnson Recent Developments and Future Plans
2.2 Pfizer Inc
2.2.1 Pfizer Inc Details
2.2.2 Pfizer Inc Major Business
2.2.3 Pfizer Inc Central Nervous System (CNS) Drug Product and Solutions
2.2.4 Pfizer Inc Central Nervous System (CNS) Drug Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.2.5 Pfizer Inc Recent Developments and Future Plans
2.3 Novartis AG
2.3.1 Novartis AG Details
2.3.2 Novartis AG Major Business
2.3.3 Novartis AG Central Nervous System (CNS) Drug Product and Solutions
2.3.4 Novartis AG Central Nervous System (CNS) Drug Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.3.5 Novartis AG Recent Developments and Future Plans
2.4 GSK
2.4.1 GSK Details
2.4.2 GSK Major Business
2.4.3 GSK Central Nervous System (CNS) Drug Product and Solutions
2.4.4 GSK Central Nervous System (CNS) Drug Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.4.5 GSK Recent Developments and Future Plans
2.5 Eli Lilly
2.5.1 Eli Lilly Details
2.5.2 Eli Lilly Major Business
2.5.3 Eli Lilly Central Nervous System (CNS) Drug Product and Solutions
2.5.4 Eli Lilly Central Nervous System (CNS) Drug Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.5.5 Eli Lilly Recent Developments and Future Plans
2.6 Teva
2.6.1 Teva Details
2.6.2 Teva Major Business
2.6.3 Teva Central Nervous System (CNS) Drug Product and Solutions
2.6.4 Teva Central Nervous System (CNS) Drug Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.6.5 Teva Recent Developments and Future Plans
2.7 Otsuka Pharmaceutical Co., Ltd
2.7.1 Otsuka Pharmaceutical Co., Ltd Details
2.7.2 Otsuka Pharmaceutical Co., Ltd Major Business
2.7.3 Otsuka Pharmaceutical Co., Ltd Central Nervous System (CNS) Drug Product and Solutions
2.7.4 Otsuka Pharmaceutical Co., Ltd Central Nervous System (CNS) Drug Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.7.5 Otsuka Pharmaceutical Co., Ltd Recent Developments and Future Plans
2.8 Biogen Inc
2.8.1 Biogen Inc Details
2.8.2 Biogen Inc Major Business
2.8.3 Biogen Inc Central Nervous System (CNS) Drug Product and Solutions
2.8.4 Biogen Inc Central Nervous System (CNS) Drug Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.8.5 Biogen Inc Recent Developments and Future Plans
2.9 Boehringer Ingelheim
2.9.1 Boehringer Ingelheim Details
2.9.2 Boehringer Ingelheim Major Business
2.9.3 Boehringer Ingelheim Central Nervous System (CNS) Drug Product and Solutions
2.9.4 Boehringer Ingelheim Central Nervous System (CNS) Drug Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.9.5 Boehringer Ingelheim Recent Developments and Future Plans
2.10 Roche
2.10.1 Roche Details
2.10.2 Roche Major Business
2.10.3 Roche Central Nervous System (CNS) Drug Product and Solutions
2.10.4 Roche Central Nervous System (CNS) Drug Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.10.5 Roche Recent Developments and Future Plans
2.11 UCB
2.11.1 UCB Details
2.11.2 UCB Major Business
2.11.3 UCB Central Nervous System (CNS) Drug Product and Solutions
2.11.4 UCB Central Nervous System (CNS) Drug Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.11.5 UCB Recent Developments and Future Plans
2.12 Tekeda
2.12.1 Tekeda Details
2.12.2 Tekeda Major Business
2.12.3 Tekeda Central Nervous System (CNS) Drug Product and Solutions
2.12.4 Tekeda Central Nervous System (CNS) Drug Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.12.5 Tekeda Recent Developments and Future Plans
2.13 Shanghai Fosun
2.13.1 Shanghai Fosun Details
2.13.2 Shanghai Fosun Major Business
2.13.3 Shanghai Fosun Central Nervous System (CNS) Drug Product and Solutions
2.13.4 Shanghai Fosun Central Nervous System (CNS) Drug Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.13.5 Shanghai Fosun Recent Developments and Future Plans
2.14 Jiangsu Nhwa Pharmaceutical Co., Ltd.
2.14.1 Jiangsu Nhwa Pharmaceutical Co., Ltd. Details
2.14.2 Jiangsu Nhwa Pharmaceutical Co., Ltd. Major Business
2.14.3 Jiangsu Nhwa Pharmaceutical Co., Ltd. Central Nervous System (CNS) Drug Product and Solutions
2.14.4 Jiangsu Nhwa Pharmaceutical Co., Ltd. Central Nervous System (CNS) Drug Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.14.5 Jiangsu Nhwa Pharmaceutical Co., Ltd. Recent Developments and Future Plans
3 麻豆原创 Competition, by Players
3.1 Global Central Nervous System (CNS) Drug Revenue and Share by Players (2019-2024)
3.2 麻豆原创 Share Analysis (2023)
3.2.1 麻豆原创 Share of Central Nervous System (CNS) Drug by Company Revenue
3.2.2 Top 3 Central Nervous System (CNS) Drug Players 麻豆原创 Share in 2023
3.2.3 Top 6 Central Nervous System (CNS) Drug Players 麻豆原创 Share in 2023
3.3 Central Nervous System (CNS) Drug 麻豆原创: Overall Company Footprint Analysis
3.3.1 Central Nervous System (CNS) Drug 麻豆原创: Region Footprint
3.3.2 Central Nervous System (CNS) Drug 麻豆原创: Company Product Type Footprint
3.3.3 Central Nervous System (CNS) Drug 麻豆原创: Company Product Application Footprint
3.4 New 麻豆原创 Entrants and Barriers to 麻豆原创 Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 麻豆原创 Size Segment by Type
4.1 Global Central Nervous System (CNS) Drug Consumption Value and 麻豆原创 Share by Type (2019-2024)
4.2 Global Central Nervous System (CNS) Drug 麻豆原创 Forecast by Type (2025-2030)
5 麻豆原创 Size Segment by Application
5.1 Global Central Nervous System (CNS) Drug Consumption Value 麻豆原创 Share by Application (2019-2024)
5.2 Global Central Nervous System (CNS) Drug 麻豆原创 Forecast by Application (2025-2030)
6 North America
6.1 North America Central Nervous System (CNS) Drug Consumption Value by Type (2019-2030)
6.2 North America Central Nervous System (CNS) Drug Consumption Value by Application (2019-2030)
6.3 North America Central Nervous System (CNS) Drug 麻豆原创 Size by Country
6.3.1 North America Central Nervous System (CNS) Drug Consumption Value by Country (2019-2030)
6.3.2 United States Central Nervous System (CNS) Drug 麻豆原创 Size and Forecast (2019-2030)
6.3.3 Canada Central Nervous System (CNS) Drug 麻豆原创 Size and Forecast (2019-2030)
6.3.4 Mexico Central Nervous System (CNS) Drug 麻豆原创 Size and Forecast (2019-2030)
7 Europe
7.1 Europe Central Nervous System (CNS) Drug Consumption Value by Type (2019-2030)
7.2 Europe Central Nervous System (CNS) Drug Consumption Value by Application (2019-2030)
7.3 Europe Central Nervous System (CNS) Drug 麻豆原创 Size by Country
7.3.1 Europe Central Nervous System (CNS) Drug Consumption Value by Country (2019-2030)
7.3.2 Germany Central Nervous System (CNS) Drug 麻豆原创 Size and Forecast (2019-2030)
7.3.3 France Central Nervous System (CNS) Drug 麻豆原创 Size and Forecast (2019-2030)
7.3.4 United Kingdom Central Nervous System (CNS) Drug 麻豆原创 Size and Forecast (2019-2030)
7.3.5 Russia Central Nervous System (CNS) Drug 麻豆原创 Size and Forecast (2019-2030)
7.3.6 Italy Central Nervous System (CNS) Drug 麻豆原创 Size and Forecast (2019-2030)
8 Asia-Pacific
8.1 Asia-Pacific Central Nervous System (CNS) Drug Consumption Value by Type (2019-2030)
8.2 Asia-Pacific Central Nervous System (CNS) Drug Consumption Value by Application (2019-2030)
8.3 Asia-Pacific Central Nervous System (CNS) Drug 麻豆原创 Size by Region
8.3.1 Asia-Pacific Central Nervous System (CNS) Drug Consumption Value by Region (2019-2030)
8.3.2 China Central Nervous System (CNS) Drug 麻豆原创 Size and Forecast (2019-2030)
8.3.3 Japan Central Nervous System (CNS) Drug 麻豆原创 Size and Forecast (2019-2030)
8.3.4 South Korea Central Nervous System (CNS) Drug 麻豆原创 Size and Forecast (2019-2030)
8.3.5 India Central Nervous System (CNS) Drug 麻豆原创 Size and Forecast (2019-2030)
8.3.6 Southeast Asia Central Nervous System (CNS) Drug 麻豆原创 Size and Forecast (2019-2030)
8.3.7 Australia Central Nervous System (CNS) Drug 麻豆原创 Size and Forecast (2019-2030)
9 South America
9.1 South America Central Nervous System (CNS) Drug Consumption Value by Type (2019-2030)
9.2 South America Central Nervous System (CNS) Drug Consumption Value by Application (2019-2030)
9.3 South America Central Nervous System (CNS) Drug 麻豆原创 Size by Country
9.3.1 South America Central Nervous System (CNS) Drug Consumption Value by Country (2019-2030)
9.3.2 Brazil Central Nervous System (CNS) Drug 麻豆原创 Size and Forecast (2019-2030)
9.3.3 Argentina Central Nervous System (CNS) Drug 麻豆原创 Size and Forecast (2019-2030)
10 Middle East & Africa
10.1 Middle East & Africa Central Nervous System (CNS) Drug Consumption Value by Type (2019-2030)
10.2 Middle East & Africa Central Nervous System (CNS) Drug Consumption Value by Application (2019-2030)
10.3 Middle East & Africa Central Nervous System (CNS) Drug 麻豆原创 Size by Country
10.3.1 Middle East & Africa Central Nervous System (CNS) Drug Consumption Value by Country (2019-2030)
10.3.2 Turkey Central Nervous System (CNS) Drug 麻豆原创 Size and Forecast (2019-2030)
10.3.3 Saudi Arabia Central Nervous System (CNS) Drug 麻豆原创 Size and Forecast (2019-2030)
10.3.4 UAE Central Nervous System (CNS) Drug 麻豆原创 Size and Forecast (2019-2030)
11 麻豆原创 Dynamics
11.1 Central Nervous System (CNS) Drug 麻豆原创 Drivers
11.2 Central Nervous System (CNS) Drug 麻豆原创 Restraints
11.3 Central Nervous System (CNS) Drug Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 Industry Chain Analysis
12.1 Central Nervous System (CNS) Drug Industry Chain
12.2 Central Nervous System (CNS) Drug Upstream Analysis
12.3 Central Nervous System (CNS) Drug Midstream Analysis
12.4 Central Nervous System (CNS) Drug Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
Johnson & Johnson
Pfizer Inc
Novartis AG
GSK
Eli Lilly
Teva
Otsuka Pharmaceutical Co., Ltd
Biogen Inc
Boehringer Ingelheim
Roche
UCB
Tekeda
Shanghai Fosun
Jiangsu Nhwa Pharmaceutical Co., Ltd.
听
听
*If Applicable.
